Schizophrenia Clinical Trial
Official title:
Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders
Persons with serious mental illness (SMI) are at increased risk of cardiovascular disease (CVD). The goals of this study are to test a treatment, Life Goals Collaborative Care to help promote health behavior change and improve mental health and physical health-related quality of life, as well as to get feedback from patients and providers on what is needed to help better coordinate the physical and mental health care of these patients.
Background: VA patients with serious mental illnesses (SMI- e.g., schizophrenia, bipolar
disorder) die an average of 13-18 years earlier compared to the general U.S. population,
mostly from cardiovascular disease (CVD). Increased risk of CVD and related risk factors in
persons with SMI is attributed to patient, provider, and system-level barriers including
unhealthy behaviors exacerbated by mental health-related symptoms and barriers to access and
continuity of care between physical and mental health services.
Objectives: The primary aim of this randomized controlled effectiveness trial (RCT) is to
determine whether VA patients with SMI receiving Life Goals Collaborative Care (LGCC), a
program that combines customized behavioral change strategies with chronic care management
for SMI will experience, within 12 months: a) improved medical outcomes (e.g., reduced CVD
risk factors, improved physical health-related quality of life), b) improved mental health
outcomes, including reduced psychiatric symptoms or improved mental health-related quality
of life or c) improved health behaviors, compared to VA patients with SMI receiving enhanced
treatment as usual (i.e., dissemination of health behavior change materials in addition to
standard VA medical and psychiatric care). Secondary aims that will inform further
implementation of LGCC will be to assess utilization and cost differences of LGCC versus
treatment as usual, determine the patient factors associated with LGCC treatment response,
and identify the organizational factors associated with LGCC implementation.
Methods: LGCC is a groundbreaking psychosocial and behavior change intervention that is
based on the Chronic Care Model (CCM) and consists of 1) 10 self-management sessions that
cover personal goal-setting and mental health symptom management reinforced through healthy
lifestyles; 2) medical care management that includes identification of patient medical risk
factors, monitoring of patient symptoms and medical needs via a registry over time; and 3)
support for provider guidelines and community linkages. The investigators will enroll
individuals diagnosed with SMI and a CVD risk factor who are receiving care within the VA
Ann Arbor Healthcare System mental health clinic, and who will be randomized to receive LGCC
or enhanced treatment as usual. Key outcomes include changes in CVD risk factors (e.g.,
blood pressure, BMI), psychiatric symptoms, health-related quality of life, health behaviors
(e.g., physical activity), and inpatient and outpatient use assessed at 6 and 12 months.
Impact: This study addresses VA HSR&D research priorities related to mental health and care
of complex, chronic conditions, and is consistent with the priorities of the VHA's Office of
Mental Health Services (Patient Care Services), 10NC, and the National Center for Health
Promotion and Disease Prevention. Serious mental illness (SMI) is associated with
significant disability, decreased quality of life, and a decreased life span. The VA is
undergoing two major quality improvement initiatives: the Patient-Aligned Care Team (PACT),
which involves enhanced access and continuity of care based on Chronic Care Model (CCM)
principles, and dissemination of behavioral medicine programs. However, to date these
programs have not been fully adapted to address gaps in quality or outcomes of care for
Veterans with SMI. Findings from this RCT will inform ongoing VA transformational
initiatives around systems redesign and behavioral medicine programs for Veterans with SMI
and determine whether a customized CCM-behavioral medicine strategy is most effective in
improving outcomes for this vulnerable group.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |